KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Non-cash Items: 2011-2025

Historic Non-cash Items for Ionis Pharmaceuticals (IONS) over the last 10 years, with Sep 2025 value amounting to $37.2 million.

  • Ionis Pharmaceuticals' Non-cash Items fell 31.24% to $37.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.2 million, marking a year-over-year decrease of 31.24%. This contributed to the annual value of $43.7 million for FY2024, which is 44.36% down from last year.
  • As of Q3 2025, Ionis Pharmaceuticals' Non-cash Items stood at $37.2 million, which was down 12.06% from $42.3 million recorded in Q2 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Non-cash Items peaked at $101.8 million during Q1 2021, and registered a low of $9.2 million during Q4 2021.
  • In the last 3 years, Ionis Pharmaceuticals' Non-cash Items had a median value of $51.9 million in 2025 and averaged $54.1 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first slumped by 83.58% in 2021, then surged by 663.66% in 2023.
  • Quarterly analysis of 5 years shows Ionis Pharmaceuticals' Non-cash Items stood at $9.2 million in 2021, then rose by 12.10% to $10.3 million in 2022, then skyrocketed by 663.66% to $78.5 million in 2023, then tumbled by 44.36% to $43.7 million in 2024, then tumbled by 31.24% to $37.2 million in 2025.
  • Its last three reported values are $37.2 million in Q3 2025, $42.3 million for Q2 2025, and $51.9 million during Q1 2025.